The current paradigm of microbial virulence is largely pathogencentric. Key factors considered to affect virulence include cytopathic effects, tissue tropism, replication and growth rates of microbial pathogens. The impact of the host's immune system is also largely viewed through the prism of its impact on pathogen clearance. However, it is increasingly clear that inflammation is a critical determinant for pathogen virulence. For example, although pigtailed macaques (Macaca nemestrina) and African green monkeys (Chlorocebus sabaeus) support viral replication equally well, AIDS-like syndrome can be observed in M. nemestrina but not in C. sabaeus. It has been suggested that this distinction arises from differences in the magnitudes of inflammatory responses in the two systems 1 . Sepsis is another important health threat that highlights the need to better understand the molecular basis of inflammation caused by infection. Despite the availability of antibiotics, the mortality and hospitalization caused by severe sepsis increased rapidly between 1993 and 2003, causing ~200,000 annual deaths in the United States alone 2 .
Among the best defined causes of inflammation are the pathogenassociated molecular patterns (PAMPs) that interact with patternrecognition receptors, such as Toll 3 or Toll-like receptors (TLR) 4 and Nod-like receptors (NLR) 5, 6 . As PAMPs should be cleared after the bacteria are eliminated by antibiotics, the fact that antibiotics cannot cure sepsis suggests that PAMPs are not the only factors responsible for sepsis. Another source of inflammation is the danger-(or damage)-associated molecular patterns (DAMPs) 7 . These conserved intracellular structures are exposed after host cell death, often as a consequence of necrosis or secondary necrosis following apoptosis 8 . The role of high-mobility globulin B1 (HMGB1) in the pathogenesis of sepsis 9 demonstrates the critical role played by host recognition of DAMPs in sepsis-associated inflammation. However, although DAMPs released during infection may also trigger inflammation through TLR and/or NLR receptors [10] [11] [12] , our recent studies have indicated that the host response to DAMPs is negatively regulated by interactions of CD24 with SiglecG (mouse) or SIGLEC10 (the human homolog of mouse SiglecG) 13 . Because inflammation caused by DAMPs is likely limited unless the interaction of CD24 with SiglecG/10 is disrupted, it is intriguing to consider the possibility that pathogens may disable the interaction of CD24 with SiglecG/10 during infection.
SiglecG/10 belongs to a super family of immunoglobulin-like lectins defined by their ability to recognize sialic acid-containing structures 14 . Human SIGLEC10 binds to both mouse and human CD24 (ref. 13 ). However, as human and mouse have different sialic acids 15 , SiglecG and SIGLEC10 may have a somewhat different repertoire of endogenous ligands. As most Siglec family members contain ITIM-or ITIM-like motifs and many are known to be associated with SHP-1 and/or SHP-2 (ref. 14) , it has been suggested that Siglecs may negatively regulate cellular activation during immune recognition. Accordingly, sialic acid-based pattern recognition negatively regulates both antibody production [16] [17] [18] and neutrophil activation 19 . However, whether sialic acid-based pattern recognition may Amelioration of sepsis by inhibiting sialidase-mediated disruption of the cD24-siglecG interaction Suppression of inflammation is critical for effective therapy of many infectious diseases. However, the high rates of mortality caused by sepsis attest to the need to better understand the basis of the inflammatory sequelae of sepsis and to develop new options for its treatment. In mice, inflammatory responses to host danger-associated molecular patterns (DAMPs), but not to microbial pathogen-associated molecular patterns (PAMPs), are repressed by the interaction of CD24 and SiglecG (SIGLEC10 in human). Here we use an intestinal perforation model of sepsis to show that microbial sialidases target the sialic acid-based recognition of CD24 by SiglecG/10 to exacerbate inflammation. Sialidase inhibitors protect mice against sepsis by a mechanism involving both CD24 and Siglecg, whereas mutation of either gene exacerbates sepsis. Analysis of sialidase-deficient bacterial mutants confirms the key contribution of disrupting sialic acid-based pattern recognition to microbial virulence and supports the clinical potential of sialidase inhibition for dampening inflammation caused by infection.
be disrupted by sialidases during infection to exacerbate pathogen virulence does not appear to have been investigated. Especially as sialidases have been identified as virulence factors for many pathogens [20] [21] [22] [23] , we used a mouse model of polybacterial sepsis to investigate this possibility. We observed that ablation of either CD24 or SiglecG increased mortality and that the protective effect of the CD24-SiglecG interaction requires sialylation of CD24 and can be attained through the expression of sialylated CD24 on dendritic cells. Sialidases make a critical contribution to inflammation and mortality associated with sepsis.
RESULTS

A role for CD24 and SiglecG in polybacterial sepsis
We used cecal ligation and puncture (CLP) 24 as the basic model to evaluate the potential contribution of the CD24-SiglecG interaction in lethal sepsis, with two different procedures causing different rates of mortality in wild-type (WT) mice. First, we treated mice with antibiotics after CLP both to mimic the clinical setting and to help demonstrate that the CD24-SiglecG interaction regulates virulence of sepsis even when bacterial growth is inhibited. Use of a 23G3/4 needle for puncture ensured that the majority of the WT mice survived the procedure. The antibiotic was highly effective as no bacteria were isolated in the blood samples from antibiotic-treated mice (data not shown). Whereas 70% of WT mice survived the entire period of observation, the overwhelming majority of the mice with targeted mutation of either CD24 or Siglecg died within 48 h (Fig. 1a) . Consistent with the increased mortality of the two classes of mutant mice, their levels of IL-6, MCP-1 and TNFα were substantially higher relative to WT controls (Fig. 1b) . Besides IL-6 and TNFα, levels of C5a were also somewhat higher (Supplementary Fig. 1a) . However, the levels of MIF were not higher in either CD24 −/− or Siglecg −/− mice (Supplementary Fig. 1b ). npg Second, to substantiate the protective role for both CD24 and Siglecg in sepsis, we tested the impact of the targeted mutations in a more severe model of sepsis, which involves using a larger needle for puncture. To reveal the potential effect of mutations on bacterial burden in the bloodstream, the mice were not treated with an antibiotic. Targeted ablation of either CD24 or Siglecg resulted in significantly (P < 0.001) accelerated onset of mortality and higher rates of overall mortality following CLP (Fig. 1c) . However, the bacterial burden in the bloodstream was unaffected by either mutation (Fig. 1d) . As most bacteria in the cecum are obligate anaerobes that cannot be detected, our assay did not address whether bacterial growth in hypoxic environments may be affected. The higher mortality in the mice deficient in either CD24 or Siglecg corresponds to significantly (P < 0.01) higher levels of inflammatory cytokines (Fig. 1e) . In fact, the inflammatory cytokines were elevated in WT mice only after 24 h (Fig. 1f) . Nevertheless, the magnitude of cytokine elevation does not explain the overall increase of mortality in the more severe model. The presence of more live bacteria may have also contributed to the increased virulence. Compared to WT counterparts, the lungs, kidneys and livers of CD24 −/− and Siglecg −/− mice showed severe hemorrhage and venous congestion (Fig. 1g) . The kidney sections showed acute tubular necrosis. Organs from mice undergoing sham surgery did not exhibit these abnormalities (Supplementary Fig. 2 ). Because CD24-SiglecG interaction repressed dendritic cell response to DAMPs 13 , we produced transgenic mice expressing CD24 under the control of the CD11c promoter 25, 26 . Upon crossing into the CD24 −/− background, CD11c + MHC class II + cells expressed high levels of CD24, comparable to those seen in WT controls (Fig. 2a) . Although detectable, levels of CD24 found in the MHC class II + CD11c − cells were about 50-fold lower than in their WT counterparts. The transgenic mice had a better survival rate (Fig. 2b) , although the burden of live bacteria in the bloodstream was unaffected by expression of the transgene (Fig. 2c) . Corresponding to better survival rates, levels of inflammatory cytokines were lower in the transgenic mice than in their CD24-deficient littermates (Fig. 2b,d ). Therefore, CD24 expressed predominantly on CD11c + cells promoted survival and suppressed inflammation without affecting bacterial burden.
The CD24-SIGLEC10 interaction depends on CD24 sialylation The impact of genetic disruption of the CD24-SiglecG interaction indicates that this pathway negatively regulates inflammation during sepsis. This raises the intriguing possibility that microbial pathogens may target this interaction to exacerbate sepsis. Because sialidases are virulence factors in many pathogenic bacteria 20 , and because sialic acid-based pattern recognition is a cardinal feature of Siglecs 14 , we considered the possibility that bacterial sialidases may exacerbate sepsis by desialylating CD24. To determine whether the interaction of human CD24 with human SIGLEC10 may be susceptible to bacterial sialidases in vitro, we treated CD24Fc, a fusion of the extracellular domain of human CD24 to the Fc fragment of human IgG1, with recombinant sialidases from S. pneumoniae, Clostridium perfringens and Vibrio cholerae. The interaction between CD24 and SIGLEC10 fusion proteins was measured by co-immunoprecipitation and a solid-phase binding assay. All three sialidases abolished the interaction of CD24 with SIGLEC10 ( Fig. 3a) and altered the mobility of CD24Fc, presumably due to both a reduction in molecular weight and the formation of SDSresistant oligomers. Consistent with the reported specificity of SIGLEC10Fc 27 , the CD24-SIGLEC10 interaction was inhibited by either α2-3-or α2-6-linked N-acetyl lactosamine, although the α2-6 sialoside was more potent (Fig. 3b) . We used CD24Fc desialylated by sialidase treatment with and without additional sialyltransferaseresialylation ( Supplementary Fig. 3 ) to substantiate these observations. Either α2-3 or α2-6 resialylation was sufficient to restore CD24-SIGLEC10 interaction, although α2-6-resialylated CD24Fc exhibited better binding (Fig. 3c,d ). Nevertheless, as the α2-6 sialylation is less abundant than the α2-3 sialylation ( Supplementary  Fig. 3 ), untreated CD24Fc required α2-3 sialylation for binding to SIGLEC10. Moreover, a >20-fold excess of desialylated CD24 failed to enable significant binding to plate-coated SIGLEC10Fc (Fig. 3d) . Therefore, apparent variations in the amounts of CD24Fc recovered after enzymatic treatment (Fig. 3a) , as judged by reactivity to anti-CD24, do not explain the almost complete lack of CD24-SIGLEC10 interaction after sialidase treatment (Fig. 3a-d) . In combination, the data of sialidase digestion of CD24Fc and inhibition of CD24-SIGLEC10 interaction by sialosides suggest that both α2-3 and α2-6-linked sialosides can interact with SIGLEC10.
Desialylation of dendritic cells increases their response to DAMPs
To determine whether bacterial sialidase exacerbates inflammatory response to DAMPs, we treated dendritic cells from WT, CD24 −/− and Siglecg −/− mice with sialidase and tested their responses to HMGB1 and HSP70. Desialylation of WT dendritic cells, but not CD24 −/− and Siglecg −/− dendritic cells, significantly (P < 0.01) increased the production of inflammatory cytokines (Fig. 3e) . Thus, even though the sialidase used has a large array of substrates, sialidase's requirement for both Siglecg and CD24 for its biological function provided genetic evidence that disruption of CD24-SiglecG interaction is responsible for the enhancement of cytokine production by sialidase. To test whether desialylation affects CD24 binding to HMGB1, we used a pull-down assay to measure the effect of desialylation on (c) Transgenic expression of CD24 had no effect on blood bacterial burden at 24 h after CLP (n = 5).
(d) CD24 on CD11c + cells suppressed production of inflammatory cytokines at 24 h (n = 5). The protection by CD24 against lethality and cytokine production was observed in four independent experiments. CFU data are representative of those from two independent experiments. npg CD24Fc binding to HMGB1. Desialylated CD24Fc did not abrogate its binding to HMGB1 (Fig. 3f) . Thus, disruption of CD24-HMGB1 interaction is unlikely responsible for enhanced cytokine production by dendritic cells.
Disruption of the CD24-SiglecG/10 interaction during polybacterial sepsis We next tested the potential role for sialidase in promoting inflammation in the CLP model. After CLP, we observed a clear elevation of serum sialidase activity (Fig. 4a) . Sera from mice with sham surgery did not show a significant increase in sialidase activity. Moreover, as a lipopolysaccharide treatment that induced a strong inflammatory response did not elevate serum sialidase activity, inflammation alone was insufficient to account for the elevated sialidase activity. The bacteria released appear sufficient to cause the observed increase in sialidase activity as antibiotic-treated mice also show elevated sialidase levels ( Supplementary Fig. 4) . Regardless of mouse genotypes, the sera from CLP mice, but not those from controls subjected to sham surgery, disrupted the interaction of CD24 with SIGLEC10 (Fig. 4b) .
To determine whether polybacterial sepsis ablates the CD24-SIGLEC10 interaction, we compared both total CD24 levels and SIGLEC10-binding activity in the spleen cells in sham-and CLP-treated mice. Although the total level of CD24 was not lower in the CLP group (Fig. 4c) , substantially less binding by SIGLEC10 was observed by flow cytometry (Fig. 4d) . Thus, sepsis disrupted CD24-binding to SIGLEC10, the human homolog of mouse SiglecG.
To confirm that SiglecG binding to CD24 is also affected, we generated a SiglecGFc fusion protein for analysis by flow cytometry. A similar reduction in SiglecGFc binding to spleen cells of septic mice was observed (Fig. 4e,f) . Importantly, double mutations (117Y→A; 120R→A) of the sialic acid-binding site in SiglecG abrogated the binding to spleen cells (Fig. 4f) . Therefore, the defective binding to SiglecGFc in CLP-treated mice resulted from desialylation. Corresponding to lower SiglecG/10 binding activity, higher electrophoresis mobility was observed in CD24 isolated from the spleen cells of the CLP mice (Fig. 4g) . Correspondingly, we also observed significantly less binding of lectins that recognize either α2-3-, or α2-6-linked sialic acids in both total spleen cells (Fig. 4h) and the gated CD11c + subset (Fig. 4i) .
Potential for treating polybacterial sepsis by targeting sialidase
To test the role of bacterial sialidases in the pathogenesis of sepsis, we synthesized two sialidase inhibitors, 2,3-dehydro-2-deoxy-N-acetylneuraminic acid (Neu5Ac2en) and 2,3-dehydro-2-deoxy-N-glycolylneuraminic acid (NeuGc2en) 28 . We first tested their ability to inhibit sialidase activity in mouse serum after CLP. Whereas Neu5Ac2en had a minimal effect on the sialidase activity, Neu5Gc2en partially inhibited the activity (Fig. 5a) . A combination of the two inhibitors completely inhibited the sialidase activity in the sera of septic (1 µg/ml) or HSP70 (7 nM). Cytokines in the supernatants were measured by cytokine bead array. (f) Desialylation of CD24 barely reduced CD24Fc binding to HMGB1. Control IgG1Fc, untreated and desialylated CD24 were co-incubated with HMGB1 (1 µg/ml). Protein A beads were used to pull down Fc. The amounts of HMGB1 associated with CD24Fc were determined by immunoblotting with anti-HMGB1 monoclonal antibody. The data shown are representative of two to five independent experiments. DeSia, desialylation; 2-3 and 2-6ST: α2-3-, α2-6-resialylation, respectively. npg mice. Importantly, the sialidase inhibitors significantly (P = 0.0018) lowered the mortality caused by sepsis (Fig. 5b) . To confirm that the sialidase inhibitors protect mice by preserving the integrity of CD24-SiglecG interaction, we tested their activity in mice deficient in either Siglecg or CD24. No protection was observed if either gene was deleted (Fig. 5b) . Therefore, the inhibitory effect of the sialidase inhibitors was dependent on both CD24 and Siglecg. Regardless of the mouse strains used, the inhibitors did not significantly reduce the live bacterial burden in the blood at either 12 h ( Supplementary  Fig. 5a ) or 24 h after CLP (Supplementary Fig. 5b ). In contrast, the inhibitors reduced levels of multiple inflammatory cytokines through a mechanism dependent on both CD24 and Siglecg (Fig. 5c) . The dependence on CD24 and Siglecg demonstrates a specificity of the inhibitors and suggests that the protection is likely achieved by preserving the SiglecG-CD24 interaction. As sepsis patients often receive antibiotic treatments, we also tested whether the sialidase inhibitor works in conjunction with antibiotics. Whereas antibiotic alone had little impact on survival, sialidase inhibitors substantially increased mouse survival (Fig. 5d) . The effect of sialidase inhibitors in antibiotic-treated mice further confirms that the impact of sialidase inhibitors is probably not due to its potential inhibition of bacterial growth.
Bacterial sialidases disrupt the CD24-SiglecG interaction
To elucidate the contribution of bacterial sialidases to sepsis, we carried out PCR analysis of peritoneal washes in CLP mice to detect bacterial sialidase genes. DNA contamination was ruled out as no signal was found in aliquots of RNA that were not converted to cDNA by reverse transcriptase. PCR products were confirmed by DNA sequencing. Of the eight sialidases tested, four were expressed in the bacteria found in peritoneal washes (Supplementary Table 1 ). The broad expression of microbial sialidase genes strengthens the contention that bacterial sialidases are produced in the CLP model. Because S. pneumoniae expresses extracellular sialidases 29 and is a common cause of sepsis 30 , and as genes encoding both nanA and nanB sialidases were expressed in the peritoneum of the CLP mice (Supplementary Table 1) , we generated mutant bacteria lacking both nanA and nanB from the D39 strain (mD39) and tested their pathogenicity in WT and mutant mice. Deletion of both nanA and nanB genes eliminated the sialidase activity in the bacterial culture (Fig. 6a) . As expected, mice infected with WT S. pneumoniae exhibited higher serum sialidase activity than those infected with the mutant (Fig. 6b) . The minor increase of sialidase activity in the sera of nan − nanB − -infected mice was likely due to release of host sialidases. Consistent with elevated serum sialidase activity, WT S. pneumoniae npg infections reduced spleen-cell binding to SIGLEC10Fc. In contrast, infection by the nanA − nanB − mutant had no effect on SIGLEC10Fc binding (Fig. 6c) . Therefore, bacterial sialidases were responsible for the reduction in binding of SIGLEC10 in the spleen cells. In WT mice, WT S. pneumoniae was more virulent than the nanA − nanB − mutant, based on the onset of mortality (Fig. 6d) . As expected, S. pneumoniae was more virulent in mice deficient in either Sigelcg or CD24. However, deletion of sialidases had no effect on the pathogenesis of the bacteria in the mutant mice. Consistent with the mortality data for WT mice, WT S. pneumoniae induced higher levels of IL-6 and TNFα than the nanA − nanB − mutant 36 h after infection, although the difference 24 h after infection was insignificant (Fig. 6e) . In contrast, the nanA − nanB − mutant induced at least as much IL-6 and TNFα as the WT bacteria in CD24 −/− and Siglecg −/− mice 24 h after infection. Owing to the death of mutant mice by 36 h, the cytokine levels in mutant mice were not measured after 24 h to avoid sampling bias. As such, we were not able to assess correlations between mouse genotypes and the peak levels of inflammatory cytokines at the same time points. Analysis of colony forming units in the blood indicated that deletion of the sialidases did not reduce S. pneumoniae growth in vivo (Fig. 6f) . Thus, the bacterial sialidases control virulence of S. pneumoniae by a growth-independent mechanism. As the effect was abrogated in mice deficient in either CD24 or Siglecg, sialidases likely increase S. pneumoniae pathogenicity by targeting the CD24-SiglecG interaction. 16 to suppress production of inflammatory cytokines. Regardless of the cellular basis of CD24 function, our data demonstrate that the interaction of CD24 with SiglecG/10 is a key regulator of polybacterial sepsis. Moreover, the role of this interaction in protecting the host against inflammation associated with sepsis led us to demonstrate that its preservation provides a promising therapeutic strategy to suppress sepsis. Our evidence is consistent with the proposal that the CD24-SiglecG/10 interaction is disrupted by sialidases of multiple bacterial origins. Sialidase is expressed in both Gram-positive and Gramnegative bacteria (Supplementary Table 1) . The demonstration that sialidase activity increases in human sepsis patients 33 underscores the likelihood that our data are likely to be clinically relevant. Because desialylation of WT dendritic cells increased their response to HMGB1 and HSP70, and because the enhancement depends on expression of CD24 and SiglecG, it is likely that its impact on host response to DAMPs is achieved by disruption of the CD24-SiglecG interaction. Indeed, circulating sialidases in CLP mice reduced the interaction between CD24Fc and SIGLEC10Fc in vitro and the interaction between soluble SiglecG and its endogenous ligand in vivo.
Although the serum sialidase activity in CLP mice could be of host and/or microbial origin, our data suggest that bacterial sialidases are likely the major source of the activity. First, we documented transcripts of multiple bacterial sialidases in the peritoneal exudates of the CLP mice. Second, the elevation of sialidase activity was observed in CLP mice, but not in the lipopolysaccharide-treated mice or controls subjected to sham surgery. This eliminates the possibility that inflammation alone was sufficient to elevate sialidase activities. However, we have not ruled out the possibility that endogenous sialidase is released in the context of polybacterial sepsis. Nevertheless, it should be pointed out that as long as the sialidasemediated disruption of CD24-SiglecG/10 interaction occurred selectively in the context of infection, the sialidases of host and bacterial origins will have similar consequences.
Our genetic analyses using bacterial mutants demonstrated a critical role for sialidases in sepsis caused by a specific strain of S. pneumoniae. Although the sialidase activity is still detectable in the serum of mice infected by the sialidase mutant, the levels are functionally insignificant as the nanA − nanB − bacteria had no effect on binding of SIGLEC10Fc to spleen cells. More importantly, the nanA − nanB − mutant is less virulent than WT S. pneumoniae in WT mice when both strains are equally abundant in the bloodstream. The sialidases likely target the CD24-SiglecG interaction as the nanA − nanB − mutant is as virulent as the WT bacteria in CD24 −/− and Siglecg −/− mice. The essential requirement for CD24 and Siglecg in sialidase-mediated virulence, coupled with the lack of effect of sialidase on bacterial load in the blood, demonstrates that sialidases from S. pneumoniae are not required for optimal systemic infection. Streptococcus pneumoniae nanA may protect mice against intravascular coagulation during sepsis 34 . The different phenotype of the double mutant we report suggests that nanB may have a different function.
It is worth noting that many pathogens, including viruses and bacteria have their own sialidases, which are also known as neuraminidases 35, 36 . Both viral and bacterial sialidases have been identified as virulence factors [20] [21] [22] [23] . Until now, the role of the sialidase as a virulence factor was considered only in the context of pathogen growth. Our data demonstrate that sialidases can regulate virulence by a bacterial growth-independent mechanism through disrupting the pattern recognition that selectively represses host responses to tissue injuries 13, 31 . As tissue injury is common during infections, it is likely that the sialidases from other pathogens also affect virulence by targeting the CD24-SIGLEC10 interaction.
The current paradigm for the cause of inflammation emphasizes the interactions between PAMPs, DAMPs and their receptors 7, 37, 38 . Our data demonstrate that in addition to providing PAMPs and DAMPs, microbes may exacerbate innate immunity by disrupting sialic acid-based pattern recognition. This would further strengthen the discrimination between septic and aseptic insults 31, 32 . Therefore, an effective strategy to control excessive inflammation must target both the production and regulation of host response to DAMPs and PAMPs.
As sepsis involves multiple inflammatory cytokines and other pathological changes 39 , immunotherapies targeting individual cytokines have limited therapeutic effect 40 . For that reason, it is always difficult to link a specific cytokine to mortality. Importantly, a combination of two sialidase inhibitors conveys a significant therapeutic effect in the CLP model of polybacterial sepsis. Again, the function of the inhibitors depends on the CD24-SiglecG interaction, as mutations of either gene abrogated their therapeutic effect. Our strategy to preserve the integrity of the CD24-SiglecG/10 interaction by sialidase inhibitors may have an advantage over current options to control sepsis, as multiple cytokines and complement are regulated by the interaction of CD24 with SiglecG/10. Moreover, by providing genetic evidence for the importance of the integrity of the CD24-SiglecG/10 interaction in protection against sepsis, our data suggest that other approaches that stimulate this pathway may be explored for therapeutic intervention to suppress sepsis.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nbt/index.html.
